Search tips
Search criteria 


Logo of canfamphysLink to Publisher's site
Can Fam Physician. 1999 January; 45: 114–124.
PMCID: PMC2328074

Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.


OBJECTIVES: To present a strategy for identifying candidates for consideration of BRCA1 and BRCA2 mutation testing. To discuss the implications of identifying patients as BRCA1 or BRCA2 mutation carriers, and to provide recommendations for managing them. QUALITY OF EVIDENCE: A MEDLINE search from January 1990 to May 1998 was performed using the terms genetic breast screening, BRCA1, and BRCA2. The bibliographies of articles found were searched for further relevant titles. There are no published, randomized controlled clinical trials of management strategies for known BRCA carriers. Many recommendations for management are based on expert opinion only. MAIN FINDINGS: About 5% of women with breast cancer are carriers of genetic mutations. An accurate and detailed family history is the most important tool for identifying potential BRCA1 and BRCA2 mutation carriers. Women identified as carriers have a substantially increased risk of breast and ovarian cancer. Male carriers have a moderately increased risk of prostate cancer. Management strategies for carriers are not well studied but include increased surveillance, preventive surgery, chemoprevention, and lifestyle modification. CONCLUSION: Family physicians must be able to identify people at risk, to discuss management strategies, and when appropriate, to offer referral for consideration of genetic testing. There is an urgent need for research to determine the effectiveness of surveillance strategies, preventive surgery, chemoprevention, and lifestyle modification for BRCA1 and BRCA2 mutation carriers.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Foulkes WD, Narod SA. Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing. Clin Invest Med. 1995 Dec;18(6):473–483. [PubMed]
  • Vasen HF. Screening in breast cancer families: is it useful? Ann Med. 1994 Jun;26(3):185–190. [PubMed]
  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. [PubMed]
  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995 Dec 21;378(6559):789–792. [PubMed]
  • Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998 May;16(5):1969–1977. [PubMed]
  • Marx G. Possible function found for breast cancer genes. Science. 1997 Apr 25;276(5312):531–532. [PubMed]
  • Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997 May 15;336(20):1401–1408. [PubMed]
  • Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. [PubMed]
  • Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997 May 15;336(20):1409–1415. [PubMed]
  • Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA. 1995 Feb 15;273(7):577–585. [PubMed]
  • Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993 Apr;52(4):678–701. [PubMed]
  • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. [PubMed]
  • Easton D. Breast cancer genes--what are the real risks? Nat Genet. 1997 Jul;16(3):210–211. [PubMed]
  • Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer. 1995 Oct;72(4):805–812. [PubMed]
  • Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. [PubMed]
  • Offit K. BRCA1. A new marker in the management of patients with breast cancer? Cancer. 1996 Feb 15;77(4):599–601. [PubMed]
  • Blankson ML, Cliver SP, Goldenberg RL, Hickey CA, Jin J, Dubard MB. Health behavior and outcomes in sequential pregnancies of black and white adolescents. JAMA. 1993 Mar 17;269(11):1401–1403. [PubMed]
  • Thomas DB, Gao DL, Self SG, Allison CJ, Tao Y, Mahloch J, Ray R, Qin Q, Presley R, Porter P. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. 1997 Mar 5;89(5):355–365. [PubMed]
  • Lynch HT, Lynch J, Conway T, Watson P, Feunteun J, Lenoir G, Narod S, Fitzgibbons R., Jr Hereditary breast cancer and family cancer syndromes. World J Surg. 1994 Jan-Feb;18(1):21–31. [PubMed]
  • Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins FS, Weber BL. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA. 1993 Apr 21;269(15):1970–1974. [PubMed]
  • Harvey BJ, Miller AB, Baines CJ, Corey PN. Effect of breast self-examination techniques on the risk of death from breast cancer. CMAJ. 1997 Nov 1;157(9):1205–1212. [PMC free article] [PubMed]
  • Cannistra SA. Cancer of the ovary. N Engl J Med. 1993 Nov 18;329(21):1550–1559. [PubMed]
  • Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, Crayford TJ, Collins WP. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993 Apr 17;306(6884):1025–1029. [PMC free article] [PubMed]
  • Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993 Apr 17;306(6884):1030–1034. [PMC free article] [PubMed]
  • Cole DE, Gallinger S, McCready DR, Rosen B, Engel J, Malkin D. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? CMAJ. 1996 Jan 15;154(2):149–155. [PMC free article] [PubMed]
  • Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, McTiernan A, Offit K, Perlman J, Petersen G, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997 Mar 26;277(12):997–1003. [PubMed]
  • Littrup PJ. Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1994 Oct 1;74(7 Suppl):2016–2022. [PubMed]
  • Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med. 1995 Nov 23;333(21):1401–1405. [PubMed]
  • Pennisi VR, Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg. 1989 Winter;13(1):15–21. [PubMed]
  • Ziegler LD, Kroll SS. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol. 1991 Oct;14(5):451–454. [PubMed]
  • Stephenson J. Study shows mastectomy prevents breast cancer in high-risk women. JAMA. 1997 May 14;277(18):1421–1422. [PubMed]
  • Goodnight JE, Jr, Quagliana JM, Morton DL. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol. 1984 Jul;26(3):198–201. [PubMed]
  • Nelson NJ. Studies show prophylactic surgeries seem to reduce cancer risk. J Natl Cancer Inst. 1997 Jun 4;89(11):762–763. [PubMed]
  • Weber BL, Giusti RM, Liu ET. Developing strategies for intervention and prevention in hereditary breast cancer. J Natl Cancer Inst Monogr. 1995;(17):99–102. [PubMed]
  • Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997 May 15;336(20):1465–1471. [PubMed]
  • Tobacman JK, Greene MH, Tucker MA, Costa J, Kase R, Fraumeni JF., Jr Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 1982 Oct 9;2(8302):795–797. [PubMed]
  • Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993 May 1;71(9):2751–2755. [PubMed]
  • Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan N, Mettlin CJ, Blake CA. Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer. 1993 Jan 15;71(2 Suppl):582–588. [PubMed]
  • Gross TP, Schlesselman JJ. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol. 1994 Mar;83(3):419–424. [PubMed]
  • Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. [PubMed]
  • Goel V. Tamoxifen and breast cancer prevention: what should you tell your patients? CMAJ. 1998 Jun 16;158(12):1615–1617. [PMC free article] [PubMed]
  • Margolese RG. How do we interpret the results of the Breast Cancer Prevention trial? CMAJ. 1998 Jun 16;158(12):1613–1614. [PMC free article] [PubMed]
  • Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med. 1997 May 1;336(18):1269–1275. [PubMed]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada